Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPI-1100
- Development stage
- Discontinued
- Lead developer
- Syntara
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Inhalation
01
Overview
TPI-1100 is an investigational inhaled antisense oligonucleotide developed for the treatment of chronic obstructive pulmonary disease (COPD). It is a dual-acting RNA-silencing agent that utilizes proprietary FANA (2'-deoxy-2'-fluoro-beta-D-arabinonucleic acid) technology to target and inhibit the expression of phosphodiesterase isoforms PDE4 and PDE7. By silencing these enzymes, TPI-1100 aims to reduce airway inflammation and remodeling associated with COPD. The drug is delivered via aerosol inhalation to ensure localized pulmonary action while minimizing systemic side effects typically associated with oral small molecule PDE inhibitors. Development was initiated by Topigen Pharmaceuticals, which was later acquired by Pharmaxis.
02
Targets
PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)PDE4D (Phosphodiesterase 4D)PDE7A (Phosphodiesterase 7A)PDE4 (Phosphodiesterase 4A1)
Beyond the preview
Go deeper on TPI-1100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPI-1100.